Abstract
A series of 4‐aminoquinoline analogues and 4‐aminoquinoline‐benzoxaborole conjugates were synthesized and evaluated for their antiproliferative activities against two distinct breast cancer cell lines: MCF‐7 (estrogen receptor‐positive, ER+) and MDA‐MB‐231 (triple‐negative). Preliminary dose‐response assays revealed compound 5e , a 4‐aminoquinoline–benzoxaborole conjugate, as the most active compound against MCF‐7 cells. Structure–activity relationship (SAR) analysis indicated that the cytotoxic potency of the series increased with the length of the alkyl spacer connecting the pharmacophoric moieties. To assess selectivity, HEK‐293 cells were employed as a non‐cancerous control line, and most compounds exhibited minimal cytotoxicity, except compound 5d , which showed moderate effects. To gain preliminary structural insights, exploratory molecular docking studies were performed against the ligand‐binding domain of estrogen receptor alpha (ERα). This integrated experimental‐computational approach highlights the identification of promising preliminary hits. Overall, the findings show that 4‐aminoquinoline–benzoxaborole conjugates exhibit antiproliferative activity against breast cancer cells, with greater potency towards MCF‐7 cells.
Funding Information
  • Anusandhan National Research Foundation (YSS/2015/000879/CS)

This publication has 36 references indexed in Scilit: